Loading clinical trials...

Preliminary Clinical Study of NMN Intervention in Mild Ulcerative Colitis | Clinical Trials | Clareo Health

UNKNOWNNA

Preliminary Clinical Study of NMN Intervention in Mild Ulcerative Colitis

A Single-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Trial of Nicotinamide Mononucleotide in the Treatment of Mild Ulcerative Colitis

NCT06214078•The Third Xiangya Hospital of Central South University

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to compare the safety and efficacy of nicotinamide mononucleotide (NMN) and placebo in patients with mild ulcerative colitis (UC). The main question it aims to answer is Whether NMN can alleviate the intestinal pathology of UC patients, so as to play a role in UC treatment or adjuvant therapy. Participants will be randomized into two groups, an NMN group or a placebo group. Patients in the NMN group were treated with NMN intervention for 8 weeks. The placebo group received a placebo intervention for 8 weeks.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Age ≥18 years old, ≤75 years old;
•2. Clinical diagnosis of mild active UC patients, the diagnosis standard reference inflammatory bowel disease diagnosis and treatment of the consensus of opinion 2018.
•3. Agreed to participate in this study, and sign the informed consent.

Exclusion Criteria

•1. Patients with ALT or AST more than 2 times the upper limit of normal, TBIL more than 2 times the upper limit of normal;
•2. The creatinine clearance patients less than 60 ml/min.
•3. The intestines or other parts have severely active infection patients need to use antibiotics or antiviral drugs;
•4. Crohn's disease and intestinal tuberculosis and other chronic intestinal infectious disease, intestinal malignant tumor patients;
•5. Pregnancy and lactation women;
•6. People with diabetes or screening period more than 7.0 tendency for fasting glucose/L or glycosylated hemoglobin exceed 6.5%;
•7. With serious mental illness, such as drugs and alcohol can't cooperate with the patients;
•8. Participated in any other clinical investigator within 1 month before the screening period;
•9. The researchers determine any other disease or condition is not suitable for patients participate in the study.

Locations (1)

The Third Xiangya Hospital of Central South University

Changsha, Hunan, China

Key Dates

Start Date

February 1, 2024

Primary Completion Date

March 1, 2025

Completion Date

July 30, 2025

Last Updated

January 19, 2024

Enrollment

ESTIMATED participants

Conditions

Ulcerative Colitis Chronic Mild

Interventions

nicotinamide mononucleotide

DIETARY_SUPPLEMENT

placebo

OTHER

Contacts

Xiaoyan Wang

CONTACT

+8673188618011 912877437@qq.com

R-3750 in Patients With Mild to Moderate Ulcerative Colitis

NCT05666960

Ulcerative Colitis Chronic MildUlcerative Colitis Chronic Moderate+2 more

View study

COMPLETEDPHASE1/PHASE2

Lactobacillus Rhamnosus GG (ATCC 53103) in Mild-moderately Active UC Patients

NCT04102852

Ulcerative Colitis Chronic MildUlcerative Colitis Chronic Moderate

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 19, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Preliminary Clinical Study of NMN Intervention in Mild Ulcerative Colitis

Inclusion Criteria

Exclusion Criteria

R-3750 in Patients With Mild to Moderate Ulcerative Colitis

Lactobacillus Rhamnosus GG (ATCC 53103) in Mild-moderately Active UC Patients

Effectiveness of Fecal Microbiota Transplantation as add-on Therapy in Mild-to-moderate Ulcerative Colitis

ABI-M201 in Adult Subjects With Mildly-to-Moderately Active Ulcerative Colitis